SEC FORM
3
SEC Form 3
| FORM 3 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
|
| OMB APPROVAL |
| OMB Number: |
3235-0104 |
| Expires: |
December 31, 2014 |
| Estimated average burden |
| hours per response: |
0.5 |
|
|
1. Name and Address of Reporting Person*
(Street)
|
2. Date of Event Requiring Statement
(Month/Day/Year)
07/15/2003
|
3. Issuer Name and Ticker or Trading Symbol
VERTEX PHARMACEUTICALS INC / MA
[ VRTX ]
|
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
Director |
|
10% Owner |
| X |
Officer (give title below) |
|
Other (specify below) |
| CSO & SVP Drug Discovery |
|
5. If Amendment, Date of Original Filed
(Month/Day/Year)
|
6. Individual or Joint/Group Filing (Check Applicable Line)
| X |
Form filed by One Reporting Person |
|
Form filed by More than One Reporting Person |
|
| Table I - Non-Derivative Securities Beneficially Owned |
|---|
| 1. Title of Security (Instr.
4)
|
2.
Amount of Securities Beneficially Owned (Instr.
4)
|
3. Ownership Form: Direct (D) or Indirect (I) (Instr.
5)
|
4. Nature of Indirect Beneficial Ownership (Instr.
5)
|
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
|
|---|
| 1. Title of Derivative Security (Instr.
4)
|
2. Date Exercisable and Expiration Date
(Month/Day/Year) |
3. Title and Amount of Securities Underlying Derivative Security (Instr.
4)
|
4. Conversion or Exercise Price of Derivative Security
|
5. Ownership Form: Direct (D) or Indirect (I) (Instr.
5)
|
6. Nature of Indirect Beneficial Ownership (Instr.
5)
|
| Date Exercisable |
Expiration Date |
Title |
Amount or Number of Shares |
| Stock Option |
10/15/2003
|
07/14/2013 |
Common Stock |
200,000 |
16.32 |
D |
|
| Explanation of Responses: |
|
|
Valerie L. Andrews, Atorney-In-Fact |
07/23/2003 |
|
** Signature of Reporting Person |
Date |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. |
| * If the form is filed by more than one reporting person,
see
Instruction
5
(b)(v). |
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure. |
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. |
CONFIRMING STATEMENT
of Signature Authority
This Statement confirms that the
undersigned has authorized and designated
Kenneth S. Boger, Valerie L. Andrews,
Michelle O. Rosen and Anne L. Bruno, and
each of them acting alone, to execute and
file on behalf of the undersigned any and
all Forms 3, 4 and 5 (including any
amendments thereto) that the undersigned
may be required to file with the United
States Securities and Exchange Commission
as a result of the undersigned's ownership
of or transactions in securities of Vertex
Pharmaceuticals Incorporated. The
authority of Kenneth S. Boger, Valerie L.
Andrews, Michelle O. Rosen and Anne L.
Bruno under this Statement shall continue
until the undersigned is no longer
required to file Forms 3, 4 or 5 with
regard to the undersigned's ownership of
or transactions in securities of Vertex
Pharmaceuticals Incorporated, unless
earlier revoked in writing. The
undersigned acknowledges that Kenneth S.
Boger, Valerie L. Andrews, Michelle O.
Rosen and Anne L. Bruno are not assuming,
nor is Vertex Pharmaceuticals Incorporated
assuming, any of the undersigned's
responsibilities to comply with Section 16
of the Securities Act of 1934.
This Statement supersedes and replaces any
earlier dated Statement that the
undersigned has executed.
By: /s/ Peter Mueller
Date: July 15, 2003
